Nasdaq · Healthcare
INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
As-reported financials and recent SEC filings for INTEGRA LIFESCIENCES HOLDINGS CORP, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$1.64B
Net income
$-516.5M
Net margin
-31.6%
Diluted EPS
$-6.74
ROE
-49.5%
P/E (TTM)
—
Market cap
$1.46B
Debt / equity
0.7×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.64B | $1.61B | $1.54B | $1.56B | $1.54B |
| Gross profit | $831.6M | $882.1M | $884.7M | $970.3M | $944.6M |
| Operating income | $-493.4M | $28.4M | $111.5M | $238.9M | $197.2M |
| Net income | $-516.5M | $-6.9M | $67.7M | $180.6M | $169.1M |
| Diluted EPS | $-6.74 | $-0.09 | $0.84 | $2.16 | $1.98 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-03
View on EDGAR →42026-06-03
View on EDGAR →SD2026-05-29
View on EDGAR →SCHEDULE 13G2026-05-15
View on EDGAR →42026-05-11
View on EDGAR →42026-05-11
View on EDGAR →42026-05-11
View on EDGAR →42026-05-11
View on EDGAR →Go deeper on IART
Search INTEGRA LIFESCIENCES HOLDINGS CORP’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.